BioSpace News Archive

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its dynamic business development in fiscal year 2021.

Lacerta Therapeutics, a leader in the development of adeno-associated virus technologies for the treatment of central nervous system diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences.

Immunovia announced it will participate in Gilmartin Group’s Emerging Growth Company Showcase on August 31, 2022.

Promore Pharma AB (publ) publishes its interim report for the second quarter 2022 on 30 August 2022.

VectorY announces today that it will present a poster at the Hereditary Disease Foundation 2022 Meeting in Cambridge, Massachusetts, on August 24-27, 2022.

NightHawk Biosciences today announced the construction of an advanced biosafety level 2 (BSL-2) laboratory, adding biodefense and infectious disease capabilities to the Company’s research facilities in Research Triangle Park, North Carolina.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q2 financial results after market open on August 29, 2022.

ArcutisBiotherapeutics,Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno- dermatology, today announced the enrollment of the last subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopicdermatitis (AD).

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the first patient was treated in a first-in-human Phase 1 study to assess the safety and immune biomarkers of UNO therapy.